The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder.
Rejoyn, made by Otsuka Pharmaceutical and Click Therapeutics, is a smartphone app intended for use alongside antidepressant medications for people 22 and older who have a diagnosis of major depressive disorder. It employs a six-week program that combines a new approach called cognitive-emotional training and cognitive behavioral therapy lessons, according to a news release.
John Torous, director of the Division of Digital Psychiatry at Beth Israel Deaconess Medical Center, who was not involved in the development of Rejoyn, said that this cognitive-emotional training approach is not a well-established mechanism and that the research is still exploratory. The FDA clearance for Rejoyn was granted based on results from a clinical trial involving 386 people ages 22 to 64 who had a diagnosis of major depressive disorder that was not responsive to antidepressants.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves first drug to treat yeast ear infections in dogsThe U.S. Food and Drug Administration has approved the first drug to treat yeast ear infections in dogs.
Read more »
FDA Approves First Drug for MASHResmetirom, a thyroid hormone receptor beta-selective agonist, is the first FDA-approved medication for MASH with moderate to advanced liver fibrosis.
Read more »
FDA approves the first drug for life-threatening liver diseaseMadrigal Pharmaceuticals' new drug has become the first drug approved by the US FDA to treat NASH, a fatty liver disease.
Read more »
FDA Approves First Drug for Common, Serious Liver DiseaseMillions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.
Read more »
In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's Alzheimer's drug delayed by FDA: ‘It was unexpected’On Friday, the FDA announced it would postpone a decision on Eli Lilly's potential Alzheimer's treatment donanemab.
Read more »